Clinical Trial Innovations Webinar Series
Formal Go/No-Go decisions are a key component of early clinical development risk management. AstraZeneca's Pat Mitchell reveals the advantages and challenges when pre-defining prospective decision criteria in the trial design to better inform verdicts on a program's fate. Pat surveys the current approaches utilizing dual targets in both frequentist and Bayesian frameworks.
Bonus: Receive the slides direct to your inbox upon signing up!